GH1 and Creutzfeldt Jacob disease: Survival times in the individuals who were exposed to sCJD agent(s) by the peripheral route could be extremely long and variable; for instance, in patients that received intramuscular injection of contaminated human pituitary-derived growth hormone, the onset of clinical signs and symptoms of iatrogenic CJD could be observed between 4 and 42 years after the treatment [9].